MCM3AP and hepatocellular carcinoma: These studies suggest that overexpression of MCM3AP-AS1 is associated with poor prognosis of HCC, which is acting through different pathways, that MCM3AP-AS1 may serve as a target for HCC therapy, and that the synergistic effect of MCM3AP-AS1 knockdown with therapeutic drugs for HCC could be a direction for further research.